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There is considerable interest in the development of polypyrroleebased drug delivery systems. However,
it is not possible to incorporate drugs with limited water solubility into polypyrrole from the usual
aqueousebased electropolymerisation solutions. In this study, two drugs with poor solubility in water,
sulindac and indomethacin, were incorporated within polypyrrole films as dopants from an ethanol
econtaining electropolymerisation solution to give PPyIndo and PPySul. An organic perchlorate salt
was added to the electropolymerisation solution and the resulting perchlorate dopant anions were
released initially on reducing the PPyIndo and PPySul at 0.70 V vs SCE. The drug molecules were then re
edoped in the absence of the perchlorate salt. On reduction of the polymer films the sulindac and
indomethacin were released into an aqueous saline solution, giving approximately 0.12mg cm2 of
sulindac and 0.29mg cm2 of indomethacin over a 60min release period. The greater amounts of
indomethacin released from PPyIndo were explained in terms of higher doping levels. The doping levels
of indomethacin and sulindac were estimated at 0.28 and 0.10, respectively, using electrochemical quartz
crystal microbalance measurements.
© 2018 Elsevier Ltd. All rights reserved.1. Introduction
Conducting polymers, and in particular polypyrrole, have
received much attention in recent years and this is largely con-
nected to their wide range of potential applications that extend
from sensors and biosensors [1] to drug delivery applications
[2e11]. Polypyrrole can be easily converted between its oxidised
and reduced states and during this process anions or cations are
incorporated or released to maintain charge balance. This uptake
and release has been linked with drug delivery and consequently
there is much interest in the development of polypyrroleebased
drug delivery systems [2e11]. For anionic drugs, the drug acts as
a dopant during the electropolymerisation of the pyrrole monomer
and it is subsequently released on reduction of the polymer. To
facilitate the release of cationic species, large immobile dopants are
incorporated within the polymer and then the cations are released
on oxidation of the polypyrrole films. Using this approach, various
drug molecules, including glutamate [2], dopamine [4], chlor-
promazine [5], progesterone [6], neurotrophins [9], penicillin and).streptomycin [10] and dexamethasone [3,7,11] have been incorpo-
rated and released from polypyrrole using an electrical stimulation.
In addition to controlling the charge on the polymer backbone,
electrical stimulation gives rise to volume changes in the bulk
polymer and changes in the hydrophilic/hydrophobic character of
the polymer [12] and these have an additional effect on the delivery
of the drug.
It has been reported in a number of studies that polypyrrole has
good biocompatibility properties. Almira et al. [13] have shown that
polypyrrole substrates are suitable for the attachment and prolif-
eration of mouse stem cells, making it a good candidate for
biomedical applications where adhesion and the proliferation of
stem cells is required. George et al. [14] surgically implanted pol-
ypyrrole in the cerebral cortex of a rat and concluded that the
polypyrrole implants offered good biocompatibility properties.
These studies indicate that polypyrrole has sufficiently good
biocompatibility properties and when doped with drug molecules,
as opposed to other anions that may have some toxicity,
polypyrroleeloaded drug implants have the potential to be
employed without any toxicity concerns.
The limitations in the application of polypyrrole as a
drugedelivery system include the drug loading capacity and the
variety of drug molecules that can be used. An increase in polymer
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of drug that can be released [12]. However, the concentration
released does not increase linearly with film thickness, with
thinner films releasing a greater percentage of the incorporated
drug. More recent attempts to increase the loading and concen-
tration of the drug, include increasing the surface area of the
polymer [15], combining micelles with polypyrrole [16] or nano-
wire networks that can be used as a reservoir to store drugs [17].
These investigations have all been carried out with water sol-
uble or reasonably soluble drugs. However, there are a number of
drug molecules that have limited or poor solubility in water. The
aim of this study was to determine if drug molecules with poor
water solubility could be incorporated into polypyrrole as dopants
and subsequently released in an aqueous environment, to give a
polypyrrole drug delivery system for the release of poorly soluble
drugs. Twomedium sized drugs, with limitedwater solubility, were
selected. In order to provide a suitable concentration of the drug
molecules in solution an ethanolecontaining medium was chosen
as the electropolymerisation solution. Although there are a number
of reports describing the electropolymerisation of pyrrole in
acetonitrile or acetonitrile andwatermixtures [18,19], there are few
mentions of ethanol [20]. Therefore, the formation of the polymers
in the ethanolecontaining solution was studied initially, then re-
sults are presented and discussed on the exchange properties and
on the release of the drug molecules in an aqueous saline solution.
2. Experimental method
Cyclic voltammetry and currentetime plots were carried out
using a Solartron (Model SI 1287) potentiostat. A standard three
electrode cell was used for all experiments. A high surface area
platinum wire served as the counter electrode and a saturated
calomel (SCE) electrode was used as the reference in all experi-
ments carried out at room temperature, while a silver wire refer-
ence electrode was used at higher temperatures, designated as
AgjAgþ. The potential of this wire was measured against the SCE
reference before and after each experiment, and no significant drift
was observed. A platinum disc electrode (99.99% purity) with a
surface area of 0.125 cm2 was employed as the working electrode
(the surface area of the Pt electrode (and not the polymer) is used to
express the drug release data in mmol cm2). This electrode was
fabricated by embedding a platinum rod in a Teflon holder, which
was filled with epoxy resin and a copper wirewas threaded into the
base of the metal sample for electrical contact. The exposed surface
was polished to a mirror finish using successively smaller sizes of
diamond paste to a final size of 1 mm on a microcloth (Buehler). The
surface of the platinum electrode was then rinsed with distilled
water, cleaned in an ultrasonic bath to remove any polishing resi-
dues and finally dried in a stream of air.
The chemicals used throughout this study were purchased from
SigmaeAldrich (Analar grade reagents). Pyrrole was
vacuumedistilled and stored in the dark at 20 C, while ethanol
was distilled prior to use. However, the ethanol contains trace
amounts of water, as absolutely waterefree ethanol is difficult to
maintain. All other chemicals were used as supplied. As the drug
molecules, indomethacin sodium salt (NaIndo) and sulindac so-
dium salt (NaSul), have poor solubility in water, the electro-
polymerisation of pyrrole was carried out in ethanol at 36 or 40 C.
A 0.20M pyrrole solution was used and the conductivity of the
solutionwas increased by adding tetrabutylammonium perchlorate
(TBAP). The NaIndo was dissolved in ethanol to give a 0.20M so-
lution of NaIndo and a 0.16M solution of TBAP at 36 C. The pyrrole
was added before the electropolymerisation reaction was carried
out. The NaSul was somewhat less soluble in ethanol, and therefore
a 0.12M solution of NaSul with 0.08M TBAP was employed and theelectropolymerisation reaction was carried out at 40 C. The con-
ductivity of the final solutions was 1.78 and 1.63mS for the NaIndo
and NaSul, respectively. The concentration of TBAP was chosen to
give similar conductivities and to give a drug/TBAP ratio >1.2. The
somewhat higher temperature of 40 C was employed with sulin-
dac as the salt is slightly less soluble in ethanol.
Electrochemical quartz crystal microbalance (EQCM) experi-
ments were carried out on a Chi400 EQCM instrument. The poly-
mers were deposited onto polished gold quartz crystal electrodes
(Cambria Scientific) with an exposed surface area of 0.203 cm2. A Pt
wire and a customemade AgjAgCl reference electrode were used to
complete the cell. The cell was placed in a chamber with a heater
that was employed to control and maintain the temperature at
36 C or at 40 C. The surface morphology of the polymer samples
was obtained using a Hitachi SEM. The samples were sputter coated
with gold using an Emitech K550x gold sputter coater prior to
analysis.
The release of the two drug molecules from the polypyrrole
matrix was monitored using UVevisible spectroscopy. The poly-
mers were formed at 0.90 V vs AgjAgþ to a constant charge density
of 2.8 C cm2, they were removed from the electropolymerisation
solution and placed in ethanol at 36 C. The solution was agitated
for 20min to facilitate the diffusion of any drugs that remained
within the polymer matrix as salts. Prior to the drug release ex-
periments, the polymer was thoroughly washed in acetone, then
immersed in distilled water and polarised at 0.50 V vs SCE for a
15min period. A Cary 50 UVeVisible spectrometer was employed
to give calibration curves, which were then used to compute the
concentration of the drug released from the polypyrrole films. The
release studies were carried out in an aqueous solution of 0.10M
NaCl. All release studies were repeated three times and the stan-
dard error was calculated using Eq. (1).









3. Results and discussion
The structures of indomethacin and sulindac, presented as the
sodium salts, are shown in Fig. 1. These salts were chosen to give
anionic drug molecules that are capable of acting as dopants during
the formation of the polypyrrole matrix. Although there are very
few reports detailing the formation of polypyrrole from
ethanolecontaining solutions [20], this medium enabled the elec-
tropolymerisation of pyrrole in the presence of NaIndo and NaSul,
which have limited solubility in water.
3.1. Formation of PPyIndo and PPySul
The influence of the applied potential on the rate of electro-
polymerisation in ethanol was initially studied to determine suit-
able potentials that can be employed to deposit polymers with
good conductivity. In Fig. 2, currentetime plots and the corre-
sponding chargeetime plots are shown for the electro-
polymerisation of pyrrole in the presence of NaIndo at 0.70 V,
0.80 V and 0.90 V vs AgjAgþ at 36 C to generate PPyIndo. Similar
data, shown as chargeetime plots, are presented in Fig. 3 for the
NaSul system. As evident from Fig. 2, the rate of electro-
polymerisation increases on increasing the applied potential, which
is consistent with the higher rate of electropolymerisation at higher
potentials observed with aqueous systems. While some of the
charge is related to the deposited conducting polymer and this
charge will increase as more conducting polymer is deposited, a
Fig. 1. (a) Indomethacin sodium salt (NaIndo) and (b) sulindac sodium salt (NaSul).
Fig. 3. Chargeetime plots for the formation of PPySul at 0.70 V, 0.80 V and 0.90 V vs
AgjAgþ in the presence of 0.12M NaSul, 0.08M TBAP and 0.20M pyrrole in ethanol.
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tion of the pyrrole monomer. Therefore, the gradient of the
chargeetime plot can be used to provide an estimate of the rate of
polymer deposition, while any deviation from the linear trend
would indicate a loss in the conductivity of the deposited polymer.
The average rate of electropolymerisation at 0.90 V vs AgjAgCl was
calculated as 2.9 104 C s1 (2.32 103 C cm2 s1) for PPyIndo
and 2.5 104 C s1 (2.0 103 C cm2 s1) for PPySul. The for-
mation of PPyIndo is somewhat faster and this is probably con-
nected to the higher concentration of NaIndo used. There is little
difference between the size of the two drug molecules, the mo-
lecular weights of indomethacin and sulindac are 357 gmol1 and
356 gmol1, respectively, while the conductivity of the electro-
polymerisation solutions is similar. The chargeetime plots are
linear, giving a constant rate of electropolymerisation, with no
evidence of any loss in the conductivity of the deposited polymer.
This may be connected with the presence of ethanol. Indeed,
OvandoeMedina et al. [20], observed an increase in the electrical
conductivity of polypyrrole nanoparticles with an increase in the
alcohol content. This was attributed to a longer conjugation length.
Very good reproducibility was achieved with this system. The time
required to give a total charge of 0.35 C (2.8 C cm2) at 0.90 V vs
AgjAgþ was measured as 1200± 30 s for PPyIndo and 1400± 30 s
for PPySul. These data show that it is possible to form conducting
PPyIndo and PPySul at potentials between 0.70 V and 0.90 V vs
AgjAgþ in ethanol, and by using a constant fixed chargeFig. 2. (a) Currentetime and (b) chargeetime plots for the formation of PPyIndo at 36 C at
0.20M pyrrole dissolved in ethanol.(2.8 C cm2), similar amounts of polymer can be deposited in each
experiment.
Apart fromwater, the electropolymerisation of pyrrole has been
studied extensively in acetonitrile. In particular, the marked effect
of water on the rate of electropolymerisation of pyrrole from
acetonitrile has long been known [18,19]. This effect has been
explained in terms of the higher dielectric constant of water (80
compared to 37 for acetonitrile) which reduces the Coulombic
repulsion between the radical cations, facilitating radicaleradical
coupling [19]. An alternative explanation involves the fact that
water is a fairly strong base in acetonitrile and prevents the
acidecatalyzed formation of a pyrrole trimer,
2,20e(2,50epyrrolidinediyl) dipyrrole, by capturing the released
protons [18]. Passivation of the electrode occurs if this pyrrole
trimer is subsequently electropolymerised, resulting in partially
conjugated polypyrrole. The dielectric constant of ethanol is
considerably lower than water (V¼ 25.3 at 20 C and 22.08 at
40 C) making it a poor medium to reduce the Coulombic repulsion
between the radical cations. However, ethanol with a pKa of 1.93
compared to the pKa of pyrrole, which is 3.8 [18], is more basic
that pyrrole, facilitating the capture of the released protons and
preventing the formation of the trimer, but not deprotonating other
intermediate species that are essential during the electro-
polymerisation process. It appears that ethanol has a suitable
combination of a pKa value and dielectric constant, making it an
appropriate solvent for the electropolymerisation of pyrrole.
Micrographs are shown for the PPyIndo and PPysul in Fig. 4. The
typical cauliflower or globular structures are evident for both sys-
tems, consistent with a number of previous reports [21]. The0.70 V, 0.80 V and 0.90 V vs AgjAgþ in the presence of 0.20M NaIndo, 0.16M TBAP and
Fig. 4. SEM micrographs of PPyIndo (a) and (b) and PPySul (c) and (d) deposited at 0.90 V vs AgjAgþ to a charge of 2.8 C cm2.
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reaching diameters of about 100 mm, otherwise the morphologies
are similar. It is also clear from these micrographs that there are no
insoluble precipitates of the drug molecules on the surface. This is
different to that reported by Ryan et al. [22], where crystalelike
shards of diclofenac were seen dispersed throughout the polymer
formed in an aqueous solution. Although the diclofenac salt was
soluble in the aqueous electropolymerisation solution, the local
acidification at the polymer solution interface shifted the equilib-
rium to favour the unedissociated insoluble molecule. As the pKa
values of indomethacin and sulindac, 3.96 and 4.26 in water at
25 C, are relatively high some unedissociated drug molecules will
be formed during electropolymerisation. However, these neutral
molecules are more soluble in ethanol and are removed from the
surface enabling doping of the polymer by the remaining anionic
species.Fig. 5. (a) Steadyestate cyclic voltammograms, 20th cycle, recorded at a scan rate of
25mV s1 in the presence of 0.10M NaCl (pH 3.0) for e e e PPyIndo, PPySul and ▬▬
PPyCl (b) mass plotted as a function of applied potential for PPyIndo recorded at
5mV s1 in 0.10M NaCl e e first cycle and ▬ third cycle.3.2. Electroactivity, exchange properties and doping levels
The electroactivity and exchange properties of PPyIndo and
PPySul were studied using cyclic voltammetry and EQCM in 0.1M
NaCl, as this chlorideecontaining solution was used as the release
medium. The voltammograms recorded for PPySul and PPyIndo are
compared with a PPyCl film that was formed in an aqueous 0.10M
NaCl solution, Fig. 5. The polymer films were deposited at 0.90 V vs
AgjAgþ to a total charge of 0.35 C (2.8 C cm2). The data presented
show the 20th cycle, and at this point steadyestate conditions are
evident and the ion exchange involves the chloride and/or sodium
ions from the electrolyte. It is clear from this figure that the PPySul
and PPyIndo films are electroactive and they are reduced and oxi-
dised as the potential is cycled between the upper and lower po-
tential limits. The redox properties of PPyCl are consistent with the
expulsion of chloride anions as the polymer is reduced and the
incorporation of chloride anions as the film is oxidised. These
relatively slow events give the characteristic broad oxidation andreduction waves. The voltammogram recorded for PPySul is
somewhat different. The incorporation of chloride anions from the
solution is shifted to higher potentials, with the oxidation wave
extending from0.30 V to 0.70 V vs SCE. The broad reductionwave
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at approximately 0.10 V vs SCE. This suggests that the incorporation
of chloride anions is more difficult for the PPySul films. Similar
effects were seenwith PPyIndo, but in this case the incorporation of
chloride anions appears at a lower potential compared to PPySul.
These variations between the PPyCl formed in an aqueous solution
and the PPySul and PPyIndo formed in ethanol may be related to a
different polymer morphology or a slightly lower conductivity with
the oxidation waves being shifted to higher potentials.
As the sulindac and indomethacin are relatively large, the
incorporation of Naþ is also likely to occur on reduction of the
polymer films to give mixed ion exchange behaviour. Indeed, this is
clearly evident in Fig. 5(b) where the mass recorded using EQCM is
shown as a function of the potential for PPyIndo. The uptake of Naþ
and water molecules is evident during the first cycle, where an
increase in mass is observed at about 0.10 V vs AgjAgCl. The mass
increases at a higher rate between 0.20 V and 0.45 V vs AgjAgCl,
indicating a higher uptake of water and Naþ. The mass loss
observed between about 0.50 V and 0.80 V vs AgjAgCl can be
attributed to the expulsion of the indomethacin, indicating that
mixed ion exchange occurs. The data presented for cycle 3 are
dominated by chloride exchange. As the oxidised polymer is
reduced the previously incorporated chloride anions are now
released and this is evident from approximately 0.50 V to 0.30 V
vs AgjAgCl. Again, there is a small mass loss (about 0.04 mg V1)
observed at the lower potentials and this appears to be connected
to the release of the indomethacin dopant.
The doping levels were estimated using Eq. (2) where the
massecharge term was obtained from EQCM data. In these equa-
tions, M is the total mass of the deposited polymer, Q is the charge
reached, Mm is the mass of the monomer, Mdop is the mass of the
dopant, x is the doping level and F is Faraday's constant. As per-
chlorates were added to the electropolymerisation solution,
competitive doping will occur and Eq. (2) was modified to include
both perchlorate and the drug molecules as dopants, Eq. (3). In
Fig. 6(a), typical massecharge plots are shown for the formation of
PPyIndo and PPySul. In the case of PPyIndo, there is a short in-
duction period observed before the mass begins to increase. This
may be due to the slow diffusion of the anionic indomethacin. After
this initial induction time has elapsed, the massecharge plot be-
comes linear, with a slope of 7.5 104 g C1, indicating homoge-
nous film growth on the EQCM gold electrode. A lower
massecharge slope of 5.4 104 g C1 was obtained with sulin-
dac, indicating the incorporation of less sulindac as a dopant, Using
the massecharge slopes and allowing xTotal, Eq. (4), to vary, the
sulindac and indomethacin doping levels were estimated as aFig. 6. (a) Massecharge plots recorded during the formation of ▬ PPyIndo and  PPySu
and B PPySul.function of xTotal and these estimated values are plotted in Fig. 6(b).
It is evident from this analysis that the doping levels of sulindac are
considerably lower, reaching values of approximately 0.10, while
much higher values of 0.28 are achieved with indomethacin.
M
Q
¼ MmþMdop xð2þ xÞF (2)
M
Q








xTotal ¼ xdrug þ xClO4 (4)
There is very little difference between the size of the molecules,
Fig. 1, they both have a carboxyl group that is ionised and provides
the site for doping within the polymer matrix. However, as can be
seen in Fig. 1, the nitrogen in the indole ring of indomethacin is
replaced in the sulindac by a double bond. Because of this double
bond, the aryl substituent (aromatic ring) lies permanently in the
cis configuration, whereas there is rotation around the single bond
and more flexibility in the indomethacin molecule. This makes the
indomethacin a potentially better dopant that can be more easily
incorporated into the polymer. This is consistent with the higher
indomethacin doping levels.3.3. The amount of perchlorate doped within the polymer matrix
The amount of perchlorate doped within the polymer matrix
was determined using a spectrophotometric method, employed by
Ensafi and Rezaei [23]. This method was used as the absorbance of
the perchlorate is not sufficiently sensitive for low concentrations.
This involved adding an excess of a cationic dye, brilliant cresyl blue
(BCB), which forms an insoluble ion pair with the perchlorate
anion. The ion pair was then extracted into methyl isobutyl ketone
and the absorbance of this solution was recorded. The PPySul and
PPyIndo polymer films were polarised at 0.70 V vs SCE for 60min
in a 0.10M NaCl solution to release any perchlorate doped within
the polymer film and then the solution was analysed for the
perchlorate content as the ion pair. The amount of perchlorate
released from PPyIndo and PPySul was 2.04 108mol cm2 and
2.94 108mol cm2, respectively. As the perchlorate is a relatively
small dopant, with a low charge density, it should diffuse from the
polymer within 60min, once the polymer is reduced. Indeed, no
perchloratewas detected following a 15e30emin reduction period.l and (b) estimated doping level as a function of the total doping levels for: PPyIndo
Fig. 7. (a) UVeVisible spectra recorded for ▬ 6.0 105M Sulindac and 
6.0 105M Indomethacin dissolved in 0.10M NaCl, and calibration curves recorded in
0.10M NaCl for (b) sulindac and (c) indomethacin (n¼ 3).
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The release of indomethacin and sulindac from the polymer
films was studied in an aqueous saline solution containing 0.10M
NaCl, at a pH of 6.0 at room temperature. While NaIndo and NaSul
are soluble in ethanol, this medium is not suitable in terms of po-
tential drug delivery applications. It is difficult to obtain accurate
solubility data for the indomethacin and sulindac sodium salts in
water, with values provided by chemical suppliers ranging from
0.50 g L1 (1.4mM) to 3.59mg L1 (9.8 mM). Therefore, the solubi-
lity was estimated using UV spectroscopy and by fitting the data to
the BeereLambert law (A¼ 3cd). The UV spectra of indomethacin
and sulindac recorded in 0.10M NaCl between 200 nm and 500 nm
are shown in Fig. 7(a) where lmax appears at 327 nm, 265 nm and
201 nm for sulindac and at 266 nm, 321 nm and 203 nm for indo-
methacin. The calibration curves shown in Fig. 7(b) and (c) were
obtained for the absorption bands at the two higher lmax values.
Good linearity is seen up to about 100 mM and then as shown in
Fig. 7(b) for the sulindac system, the linearity is lost with higher
concentrations and this is consistent with the precipitation of
insoluble sulindac. The extinction coefficient, 3, was calculated as
3085M1 cm1 at 327 nm and 1135M1 cm1 at 265 nm for
sulindac, while the corresponding values for indomethacin were
1301M1 cm1 at 266 nm and 865M1 cm1 at 321 nm. These data
clearly show that both indomethacin and sulindac are soluble at mM
concentrations in 0.10M NaCl and therefore the aqueous saline
solution is a suitable medium for the release of the drugs from
polypyrrole. To ensure that the concentrations of the drugs released
from polypyrrole were within these linear calibration ranges the
volume of the release medium was altered from 120mL to 20mL,
depending on the amount of the drug released.
As perchlorates are incorporated as dopants during the forma-
tion of PPyIndo and PPySul, these anions were firstly released
at 0.70 V vs SCE over a 60min period in a 0.10M NaCl solution.
The reduced polymer was then polarised at 0.90 V vs AgjAgþ for
60min in a solution of NaIndo or NaSul, but without the perchlo-
rate salt. The TBAP salt was removed at this point as it is only
required during the electropolymerisation step and this eliminates
any incorporation of perchlorate within the polymer film. The
release profiles for the PPyIndo and PPySul are shown for the 1st,
2nd and 3rd release periods in Fig. 8. During the first release
experiment the perchlorate anion is ejected with the drug mole-
cule, and during this initial release relatively high levels of the drug
molecules are also expelled. Although the amount of indomethacin
and sulindac released decreases with further release periods,
approximately 0.80 mmol cm2 of Indo is released during the 2nd
release period, giving a good rate of drug release. Similarly,
approximately 0.38 mmol cm2 of Sul is released during the 2nd
release event. This indicates that it is possible to eliminate the
perchlorate by initially reducing the polymer to expel the
perchlorate anions and then the drug molecules can be
reeincorporated. The loss in the amount of the drugs released with
repeated reduction and oxidation steps suggests that it is more
difficult to reeoxidise the polymer to give the same levels of
doping. This may be related to a loss in the conductivity of the
polymer with repeated oxidation and reduction periods. It is also
evident from these plots that significantly lower release rates are
seen with the sulindac system. This is probably connected to the
lower doping levels estimated for PPySul, Fig. 6.
The influence of the applied potential on the release of the drugs
is shown in Fig. 9(a). The polymers were deposited at 0.90 V vs
AgjAgþ to a charge of 2.8 C cm2 and the perchlorate anions were
previously ejected and these data correspond to the second release
period. It is clear from this figure that the applied potential has a
significant influence on the drug release with a gradual increase inthe amount of the drug released as the polymer becomes increas-
ingly reduced. The release is more efficient between 0.60 V
and 0.80 V vs SCE and this corresponds with the reduction of the
polymer and is in good agreement with the EQCM data shown in
Fig. 5(b). At more negative potentials, the release rate of the drug
decreases as side reactions, mainly the hydrogen evolution reaction
at the platinum substrate, prevail. This reaction consumes charge,
limiting the reduction of the polymer and it also generates
hydrogen and the liberation of these gaseousmolecules may lead to
Fig. 8. Amount of (a) Indo released and (b) Sul released at 0.70 V vs SCE in the presence of 0.10M NaCl, over 60min; C 1st release, B 2nd release and :3rd release. Between
each release period the polymer was placed in NaIndo or NaSul for 60min at a potential of 0.90 V vs AgjAgþ (n¼ 3).
Fig. 9. (a) Amount of Indo and▐ Sul released as a function of the applied potential in the presence of 0.10M NaCl over 60min (n¼ 3, % max. error¼ 4.7%). (b) Voltammograms
recorded on cycling platinum at 25mV s1 at 40 C in 0.08M TBAP in ethanol and in the presence of 0.20M Indo and ▬ 0.12M Sul.
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inhibiting the reduction of the polymer. In addition, as shown in
Fig. 9(b), sulindac is susceptible to reduction, where the >S]O
group is reduced to a sulfide. The data shown in Fig. 9(b) were
recorded in ethanol with 0.12M NaSul dissolved in 0.08M TBAP
and for comparative purposes the voltammetry of NaIndo is shown
while the electrochemistry of platinum is also shown in the sup-
porting TBAP electrolyte. The reduction of sulindac begins at
about 0.80 V vs AgjAgþ and the current reaches 2mA cm2
at 1.2 V vs AgjAgþ. On the other hand, indomethacin shows no
electrochemistry with low currents measured between 0.80 V
and 1.4 V vs AgjAgþ. Indeed, the presence of indomethacin in the
solution inhibits the formation of the platinum oxides/hydroxides,
probably by adsorbing at the platinumesolution interface. The
sulindac released from PPySul is at a much lower concentration and
its reduction in aqueous solutions will be shifted to a lower po-
tential. This indicates that sulindac can be released without any
conversion to the sulfide at potentials between 0.40 V
and 0.70 V vs SCE.
In order to estimate how much of the drug was available for
release, release studies were carried out over a 15 h period and the
concentration of the drug released was used to give an approximate
value for the amount of the drug available for release. Using this
approach, it was estimated that 85% of sulindac and 76% of indo-
methacin is released after 1 h. These data compare well with anumber of studies with other release systems. For example, Zelenak
et al. [24], used ordered cubic nanoporous silica supports for de-
livery of indomethacin and found that the percentage of indo-
methacin released by diffusion over a 72 h period varied between
83% and 57% depending on the surface modification. These rela-
tively high quantities of drug release from the polymer may be
connected to the high charge consumed during the formation of the
polymers. The thickness of the polymer films was estimated as
5.8 mm using Faraday's Law, Eq. (5), where M is the molar mass of
pyrrole, q is the charge, A is the surface area of the electrode, z is the
number of electrons transferred, F is Faraday's constant and r is the




It is evident from Fig. 5(b) that in addition to the release of the
drug molecules that Naþ ingress, accompanied by solvated water
molecules, occurs on reduction of the polymer film, as illustrated in
Eqs. (6) and (7). This mixed ion exchange will reduce the amount of
the drug available for release. As the insertion of Naþ begins at
about 0.20 V vs AgjAgCl, the release of the drug molecules
without the incorporation of Naþ is difficult to achieve. As shown in
Fig. 9(a) it is possible to release the drug molecules at 0.10 and
0.20 V vs SCE, however the release rate is reduced considerably,
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Using the EQCM data and assuming that the doping levels
estimated during the early stages of film formation are maintained
during the formation of the bulk polypyrrole films, the amount of
indomethacin and sulindac incorporated as dopants was estimated.
Using the doping levels of 0.28 for indomethacin and 0.10 for
sulindac, and the massecharge ratios of 7.5 106 g C1 and
5.4 106 g C1 for indomethacin and sulindac, respectively,
approximately 0.42 mmol of indomethacin and 0.16 mmol of sulin-
dac are incorporated as dopants. This gives maximum release
amounts of 3.3 mmol cm2 for indomethacin and 1.24 mmol cm2
for sulindac and this corresponds with approximately 30e40% of
the drugs being released. This highlights a limitation of using pol-
ypyrrole in the development of a drug delivery system. Although it
is unlikely that all of the dopants would be expelled on reduction of
the polymer film, the mixed ion exchange behaviour will result in
lower release rates, as a high fraction of the drug is maintained
within the polymer matrix. This is clearly evident with these
mediumesized drugs with molecular weights of 356 gmol1.
Furthermore, the conformation of the molecule and its lack of
rotation has a role to play in how the drug molecule is incorporated
within the polymer matrix as illustrated from a comparison of the
sulindac and indomethacin systems.
4. Conclusions
The poorly water soluble drugs, indomethacin and sulindac,
were incorporated as dopants into polypyrrole from an
ethanolecontaining solution. Although higher temperatures were
required to generate the polymer films and a noneaqueous elec-
tropolymerisation solution was used, the polymers exhibit good
redox properties. It was not possible to form the polymers without
a supporting electrolyte that contained perchlorate anions and this
gave rise to competitive doping. However, the perchlorate anions
are relatively small and thesewere released initially on reduction of
the polymer film. The drug molecules were then reedoped within
the polymer matrix in the absence of the perchlorate anions. The
drug molecules were subsequently released on reduction of the
polymer films. As the drug molecules are relatively large,
mixedeion exchange behaviour was observed and this is clearly a
limitation in the development of polypyrrole or polypyrrole com-
posite materials as a drug delivery system. In order to avoid the
ingress of Naþ from the release medium, the drug must be released
at a potential higher than 0.05 V vs AgjAgCl, Fig. 5, which corre-
sponds to a release potential of 0.10 V vs SCE in Fig. 9.
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